Business
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
Flavio Mantelli, MD, PhD, OKYO Pharma Chief Medical Officer Dr. Mantelli will lead the clinical and regulatory strategy to advance the company’s development program in neuropathic corneal pain (NCP), leveraging urcosimod’s FDA Fast Track designation Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to
About this update from Okyo Pharma Limited
[{"type":"image","alt":"OKYO Pharma LTD","displaySize":"","headline":null,"caption":"OKYO Pharma LTD","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/a8bd0cda50c593b9f86805333401781f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z5rBQz17s3GxW5mY3tWfBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a8bd0cda50c593b9f86805333401781f","width":300,"height":113}},"lazy":false},{"type":"text","content":"Flavio Mantelli, MD, PhD, OKYO Pharma Chief Medical Officer","length":59,"tagName":"p"},{"type":"image","alt":"Dr. Mantelli will lead the clinical and regulatory strategy to advance the company’s development program in neuropathic corneal pain (NCP), leveraging urcosimod’s FDA Fast Track designation","displaySize":"","headline":null,"caption":"Dr. Mantelli will lead the clinical and regulatory strategy to advance the company’s development program in neuropathic corneal pain (NCP), leveraging urcosimod’s FDA Fast Track designation","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":800,"height":1200,"url":"https://media.zenfs.com/en/globenewswire.com/5858efd6f1eb5c45e514128296758b78"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uV_rb3nbWqKFaKN6AWbxrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE0NDA7Y2Y9d2VicA--/https://media.zenfs.com/en/globenewswire.com/5858efd6f1eb5c45e514128296758b78","width":800,"height":1200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/dRO.9U6.Pt66bIYeF4c3Rg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2MDA7aD0yNDAwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/5858efd6f1eb5c45e514128296758b78","width":800,"height":1200}}},{"type":"list","items":[{"val":[{"type":"text","content":"Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal disease","length":187,"tagName":"p"}]},{"val":[{"type":"text","content":"Dr. Mantelli will lead the clinical and regulatory strategy to advance the company’s development program in neuropathic corneal pain (NCP), leveraging urcosimod’s FDA Fast Track designation","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"This appointment, following the recent CEO app...